Related Experiment Video
Updated: Sep 27, 2026
09:07
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
BIII-890-CL. Boehringer Ingelheim
1University of Alabama at Birmingham, School of Medicine, Dept of Physical Medicine and Rehabilitation, 157 Spain Rehabilitation Center, 619 19th St South, Birmingham, AL 35249-7330, USA. JMeythal@uab.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|January 17, 2003
Abstract:
BIII-890-CL is a non-orally active sodium channel blocker under development by Boehringer Ingelheim Corp for the potential treatment of thromboembolic stroke. By April 2001, the compound was in phase II clinical trials for this indication, with trials ongoing in June 2002. The compound is also under investigation for its potential use in the treatment of pain.
